ASP4070

DRUG2 trials

Sponsors

Astellas Pharma Inc

Conditions

Cedar PollinosisRhinitis, Allergic, Seasonal

Phase 1

A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy

CompletedNCT02469688

Astellas Pharma IncCedar Pollinosis

Start: 2015-06-18End: 2016-07-26Updated: 2024-10-31

Phase 2

A Dose-finding Study of ASP4070

CompletedNCT03101267

Astellas Pharma IncRhinitis, Allergic, Seasonal

Start: 2017-04-13End: 2018-10-27Updated: 2024-11-26